SG11202002968UA - Compound having erk kinase inhibitory activity and use thereof - Google Patents

Compound having erk kinase inhibitory activity and use thereof

Info

Publication number
SG11202002968UA
SG11202002968UA SG11202002968UA SG11202002968UA SG11202002968UA SG 11202002968U A SG11202002968U A SG 11202002968UA SG 11202002968U A SG11202002968U A SG 11202002968UA SG 11202002968U A SG11202002968U A SG 11202002968UA SG 11202002968U A SG11202002968U A SG 11202002968UA
Authority
SG
Singapore
Prior art keywords
compound
inhibitory activity
kinase inhibitory
erk kinase
erk
Prior art date
Application number
SG11202002968UA
Other languages
English (en)
Inventor
Lei Li
Meiyu Geng
Ying Huang
Jian Ding
Qiong Zhang
Min Huang
Shuai Tang
Ning Shen
Yi Chen
Original Assignee
Shanghai Haihe Pharmaceutical Co Ltd
Shanghai Institute Of Materia Medica Chinese Academy Of Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Haihe Pharmaceutical Co Ltd, Shanghai Institute Of Materia Medica Chinese Academy Of Sciences filed Critical Shanghai Haihe Pharmaceutical Co Ltd
Publication of SG11202002968UA publication Critical patent/SG11202002968UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
SG11202002968UA 2017-09-30 2018-09-29 Compound having erk kinase inhibitory activity and use thereof SG11202002968UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710915493 2017-09-30
PCT/CN2018/108762 WO2019062949A1 (zh) 2017-09-30 2018-09-29 具有erk激酶抑制活性的化合物及其用途

Publications (1)

Publication Number Publication Date
SG11202002968UA true SG11202002968UA (en) 2020-04-29

Family

ID=65902341

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002968UA SG11202002968UA (en) 2017-09-30 2018-09-29 Compound having erk kinase inhibitory activity and use thereof

Country Status (15)

Country Link
US (1) US11465984B2 (ja)
EP (1) EP3702354A4 (ja)
JP (1) JP7216105B2 (ja)
KR (1) KR20200078510A (ja)
CN (1) CN109863147A (ja)
AU (1) AU2018339722B2 (ja)
BR (1) BR112020006294A2 (ja)
CA (1) CA3080623C (ja)
EA (1) EA202090888A1 (ja)
IL (1) IL273655B2 (ja)
MX (1) MX2020003240A (ja)
NZ (1) NZ763197A (ja)
SG (1) SG11202002968UA (ja)
WO (1) WO2019062949A1 (ja)
ZA (1) ZA202001823B (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023080193A1 (ja) * 2021-11-04 2023-05-11 日産化学株式会社 インドール化合物の製造方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106928216A (zh) 2015-12-31 2017-07-07 中国科学院上海药物研究所 具有erk激酶抑制活性的化合物、其制备方法和用途
WO2017125534A1 (en) * 2016-01-22 2017-07-27 Janssen Pharmaceutica Nv New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors
US11180487B2 (en) * 2016-01-22 2021-11-23 Janssen Pharmaceutica Nv Substituted cyanoindoline derivatives as NIK inhibitors

Also Published As

Publication number Publication date
EP3702354A4 (en) 2021-02-24
CA3080623C (en) 2023-10-10
IL273655B2 (en) 2023-09-01
US11465984B2 (en) 2022-10-11
AU2018339722A1 (en) 2020-04-23
MX2020003240A (es) 2020-11-24
EA202090888A1 (ru) 2021-01-27
IL273655B1 (en) 2023-05-01
BR112020006294A2 (pt) 2020-10-06
JP2020536120A (ja) 2020-12-10
KR20200078510A (ko) 2020-07-01
EP3702354A1 (en) 2020-09-02
NZ763197A (en) 2024-03-22
CN109863147A (zh) 2019-06-07
US20200247781A1 (en) 2020-08-06
IL273655A (en) 2020-05-31
JP7216105B2 (ja) 2023-01-31
CA3080623A1 (en) 2019-04-04
WO2019062949A1 (zh) 2019-04-04
AU2018339722B2 (en) 2022-06-30
ZA202001823B (en) 2022-10-26

Similar Documents

Publication Publication Date Title
ZA202001340B (en) Heterocyclic compound and use thereof
EP3486244A4 (en) NEW CONNECTION WITH FGF-INHIBITING EFFECT, PRODUCTION AND USE THEREOF
EP3620456A4 (en) COMPOUND HAVING KINASE-INHIBITING ACTIVITY, PREPARATION METHOD AND USE THEREOF
EP3337375A4 (en) BASKET AND DISHWASHER COMPRISING IT
SG10201913927VA (en) Kinase inhibitors and uses thereof
PT3621694T (pt) Inibidores de lrrc33 e sua utilização
EP3337376A4 (en) BASKET AND DISHWASHER COMPRISING IT
EP3555051A4 (en) HEPARANASE INHIBITORS AND USE THEREOF
IL280644A (en) Magnesium serine compound and its use
KR102135648B9 (ko) 항독성 또는 항병원성 활성을 갖는 레오이딘 화합물 및 이의 용도
EP3564242A4 (en) CONNECTION FOR THE SELECTIVE INHIBITION OF KINASE AND THEIR USE
SG11202012241RA (en) Erk inhibitor and use thereof
EP3409668A4 (en) NOVEL IMIDAZOLE DERIVATIVE HAVING JNK INHIBITORY ACTIVITY AND USE THEREOF
IL273655A (en) A compound with erk kinase inhibitory activity and its use
EP3246312A4 (en) Carbamate compound and use thereof
EP3246314A4 (en) Carbamate compound and use thereof
EP3246319A4 (en) Carbamate compound and use thereof
IL258370A (en) Oxa-diazaspiro compounds with analgesic activity
IL283106A (en) erk inhibitors and their uses
EP3246318A4 (en) Carbamate compound and use thereof
EP3246316A4 (en) Carbamate compound and use thereof
EP3607339A4 (en) ACTIVE MRI
EP3555071A4 (en) HEPARANASE INHIBITORS AND THEIR USE
EP3305895A4 (en) Beta-galactosidase variant having high transglycosylation activity, and use thereof
IL284285A (en) Domperidone combinations against neurodegeneration and use